Livzon Pharmaceutical Group Inc. (SHE:000513)

China flag China · Delayed Price · Currency is CNY
34.53
+0.38 (1.11%)
Apr 8, 2026, 3:04 PM CST
Market Cap27.74B +0.3%
Revenue (ttm)12.02B +1.8%
Net Income2.02B -1.8%
EPS2.27 +1.2%
Shares Out887.91M
PE Ratio15.07
Forward PE14.59
Dividend1.43 (4.15%)
Ex-Dividend DateJun 13, 2025
Volume6,208,315
Average Volume5,673,168
Open34.50
Previous Close34.15
Day's Range34.13 - 34.58
52-Week Range32.45 - 44.87
Beta0.38
RSI49.71
Earnings DateMar 24, 2026

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro... [Read more]

Sector Healthcare
Founded 1985
Employees 8,878
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000513
Full Company Profile

Financial Performance

In 2025, SHE:000513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial Statements